1/ Primary outcome at two years FU. Table 4.
Twenty-two patients (45.99%) met the primary outcome in the RDAVR group and 32 patients (66.67%) in the TAVR group. By propensity score matching analysis, there was a significant difference between both groups in favor of RDAVR (HR=0.58[95%CI:0.34;1.00], p=0.04).